SEARCH:   Advanced

Blood, 1 February 2006, Vol. 107, No. 3, pp. 1174-1177. Prepublished online as a Blood First Edition Paper on October 20, 2005; DOI 10.1182/blood-2005-05-2033. This Article Full Text Full Text (PDF) Supplemental Figures All Versions of this Article: 2005-05-2033v1 107/3/1174    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Herranz, M. Articles by Esteller, M. Search for Related Content PubMed PubMed Citation Articles by Herranz, M. Articles by Esteller, M. Related Collections Neoplasia Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief report The novel DNA methylation inhibitor zebularine is effective against the development of murine T-cell lymphoma Michel Herranz, Juan Martín-Caballero, Mario F. Fraga, Jesús Ruiz-Cabello, Juana Maria Flores, Manuel Desco, Victor Marquez, and Manel Esteller From the Cancer Epigenetics Laboratory and the Animal Facility Unit, Spanish National Cancer Centre (CNIO); the Instituto de Estudios Biofuncionales and the Pathology Department, School of Veterinary, Complutense University of Madrid; and the Medical Image Laboratory, Department of Experimental Surgery, University Hospital Gregorio Marañón, Madrid, Spain; and the Laboratory of Medical Chemistry, National Cancer Institute, National Institutes of Health (NIH), Frederick, MD. Gene silencing by CpG island promoter hypermethylation has awakened the interest for DNA demethylating agents as chemotherapy drugs. Zebularine (1-[-D-ribofuranosil]-1,2-dihydropyrimidin-2-1) has been recently described as a new DNA methylation inhibitor. Here we have studied its effects in a mouse model of radiation-induced lymphomagenesis using nuclear magnetic resonance (NMR) and positron emission tomography (PET). All control animals presented large thymic T lymphomas and died between 4 and 5.5 months. In contrast, 40% (12 of 30) of zebularine-treated animals were still alive after 1 year (Kaplan-Meier P < .001). NMR and PET imaging showed that surviving animals presented a thymus structure/volume similar to normal mice of the same age. Most important, zebularine demonstrated a complete lack of toxicity in nonirradiated control mice. DNA hypomethylation induced by zebularine occurred in association with depletion in extractable DNA methyltransferase 1 protein. Thus, our data support the role of zebularine as a DNA demethylating agent with antitumor activity and little toxicity. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. H. Beumer, J. L. Eiseman, R. A. Parise, E. Joseph, J. L. Holleran, J. M. Covey, and M. J. Egorin Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2'-Deoxycytidine in Mice Clin. Cancer Res., December 15, 2006; 12(24): 7483 - 7491. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020